Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 9/20 | 0.51 |
| ▸ | STS | P08842 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5446182 | 1.00 | TGFBR1 (0.51) | TGFBR1STSMAPTGPR119ALDH1A1 | |
| SCHEMBL5439140 | 0.90 | NAMPT (0.50) | TGFBR1STSMAPTGPR119ALDH1A1 | |
| SCHEMBL5439143 | 0.90 | NAMPT (0.50) | TGFBR1STSMAPTGPR119ALDH1A1 | |
| SCHEMBL3038682 | 0.84 | SYK (0.50) | TGFBR1GPR119 | |
| SCHEMBL14490276 | 0.82 | NAMPT (0.47) | TGFBR1STSMAPTGPR119ALDH1A1 | |
| SCHEMBL3042063 | 0.81 | SYK (0.42) | TGFBR1MAPTGPR119 | |
| SCHEMBL3042062 | 0.81 | SYK (0.42) | TGFBR1MAPTGPR119 | |
| SCHEMBL5442098 | 0.81 | TGM2 (0.55) | TGFBR1MAPTALDH1A1 | |
| SCHEMBL5442090 | 0.81 | TGM2 (0.55) | TGFBR1MAPTALDH1A1 | |
| SCHEMBL14490336 | 0.80 | NAMPT (0.53) | TGFBR1STSMAPTGPR119ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070149508-A1 | Six membered heteroaromatic inhibitors targeting resistant kinase mutations | TARGEGEN, INC. (US) | 2007-06-28 | — | — | US | disclosed |
| US-20070149508-A1 | Six membered heteroaromatic inhibitors targeting resistant kinase mutations | TARGEGEN, INC. (US) | 2007-06-28 | — | — | US | disclosed |
| US-20070149508-A1 | Six membered heteroaromatic inhibitors targeting resistant kinase mutations | TARGEGEN, INC. (US) | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149508-A1 | Six membered heteroaromatic inhibitors targeting resistant kinase mutations | ABL1, KDR, BCR | TGFBR1 2136/4885STS 1719/4885MAPT 3282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.